|Bid||151.25 x 100|
|Ask||180.00 x 100|
|Day's range||152.70 - 155.27|
|52-week range||139.36 - 206.94|
|PE ratio (TTM)||68.64|
|Dividend & yield||0.92 (0.58%)|
|1y target est||226.08|
Bilaal Mohamed believes this hidden gem could help you on the road to riches.
Neos Therapeutics (NEOS) announced the approval of its third ADHD drug Adzenys for the treatment of six years and older patients.
Shire was the seventh-largest holding in Cooperman's Omega Advisors’ portfolio in 2Q17, representing nearly 3.5% of total holdings.